Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling
Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling
复制标题
DOI：
10.1016/j.bbrc.2017.03.006
复制
发表时间：
2017-07-15
影响因子：
3.1
通讯作者：
Shibasaki, Yoshikazu
中科院分区：
文献类型：
--
作者：
Iijima, Mariko;Anai, Motonobu;Shibasaki, Yoshikazu
表皮生长因子受体（EGFR）是一种受体酪氨酸激酶，参与许多细胞功能，包括细胞生长和迁移。EGFR可以被EGF家族配体如EGF和epiregulin（EREG）激活。EREG在人类结肠癌和乳腺癌中过表达，这意味着EREG在肿瘤发生中起作用。虽然EGF家族成员共享一个受体，但尚不清楚它们的信号通路是否不同。为了研究EREG信号传导，我们建立了抗EREG抗体，其抑制EREG而不是EGF刺激的EGFR下游信号传导。虽然抗EREG抗体对细胞生长几乎没有影响，但它抑制表达EREG的自分泌癌细胞系的细胞粘附。我们的研究结果表明，抗EREG抗体是阐明EREG特异性信号通路的有价值的工具，并可作为治疗癌症的治疗候选人。(C)2017作者爱思唯尔公司出版
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase involved in many cellular functions including cell growth and migration. EGFR may be activated by EGF family ligands such as EGF and epiregulin (EREG). EREG is overexpressed in human colon and breast cancers, implying that EREG plays roles in tumorigenesis. Although EGF family members share a receptor, it is not well known whether their signaling pathways differ. In order to investigate EREG signaling, we established the anti-EREG antibody that inhibits EGFR downstream signaling stimulated by EREG but not by EGF. While the anti-EREG antibody has little effect on cell growth, it inhibits cell adhesion of EREG-expressing autocrine cancer cell lines. Our results suggest that anti-EREG antibodies represent valuable tools for elucidating EREG-specific signaling pathways, and may serve as therapeutic candidates for the treatment of cancers. (C) 2017 The Authors. Published by Elsevier Inc.